{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is ADMA Biologics, Inc. overvalued or undervalued?
As of October 17, 2025, ADMA Biologics, Inc. is fairly valued with a P/E ratio of 24, a Price to Book Value of 13.18, and an EV to EBITDA of 30.78, outperforming some peers like Protagonist Therapeutics, Inc., despite a year-to-date return of -16.27% compared to the S&P 500's 13.30%, while achieving a remarkable 3-year return of 433.83%.
ADMA Biologics Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
ADMA Biologics, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 24 and a strong return on capital employed of 40.49%. Compared to peers, it presents a favorable profile, with significant long-term performance, achieving returns of 433.83% and 532.60% over three and five years, respectively.
Is ADMA Biologics, Inc. overvalued or undervalued?
As of October 17, 2025, ADMA Biologics, Inc. is fairly valued with a P/E ratio of 24 and has significantly outperformed the S&P 500 over three years, despite short-term underperformance.
Is ADMA Biologics, Inc. overvalued or undervalued?
As of October 17, 2025, ADMA Biologics, Inc. is fairly valued with a P/E ratio of 24 and strong long-term performance, despite a year-to-date return of -16.27%, compared to the S&P 500's 13.30%.
Is ADMA Biologics, Inc. technically bullish or bearish?
As of September 8, 2025, ADMA Biologics, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD and KST, despite a bullish weekly RSI, and has underperformed the S&P 500 with year-to-date and one-year returns of -5.77% and -16.36%, respectively.
Is ADMA Biologics, Inc. overvalued or undervalued?
As of August 6, 2025, ADMA Biologics, Inc. is considered fairly valued with a P/E ratio of 24, showing significant long-term returns of 509.81% over three years, but has underperformed in the past year with a return of -16.36%.
Is ADMA Biologics, Inc. overvalued or undervalued?
As of June 18, 2025, ADMA Biologics, Inc. is considered very attractive and undervalued with a P/E ratio of 24, an EV to EBITDA of 30.78, a ROE of 55.71%, and a PEG ratio of 0.03, outperforming the S&P 500 with a 62.45% return over the past year despite a recent stock price decline.
Is ADMA Biologics, Inc. technically bullish or bearish?
As of June 13, 2025, ADMA Biologics, Inc. shows a mildly bullish trend with daily moving averages supporting this stance, but mixed weekly indicators suggest caution despite bullish monthly signals.
Who are in the management team of ADMA Biologics, Inc.?
As of March 2022, the management team of ADMA Biologics, Inc. includes Mr. Steven Elms (Independent Chairman), Mr. Adam Grossman (President and CEO), Dr. Jerrold Grossman (Vice Chairman), and independent directors Ms. Martha Demski, Mr. Bryant Fong, and Mr. Lawrence Guiheen.
What does ADMA Biologics, Inc. do?
ADMA Biologics, Inc. is a late-stage biopharmaceutical company focused on developing and marketing specialty plasma-based biologics for infectious diseases. As of March 2025, it reported net sales of $115 million and a net profit of $27 million, with a market cap of approximately $4.51 billion.
How big is ADMA Biologics, Inc.?
As of Jun 18, ADMA Biologics, Inc. has a market capitalization of $4.51 billion, with net sales of $459.38 million and net profit of $206.77 million over the latest four quarters. Shareholder's funds are $349.02 million and total assets are $498.38 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
